NYSE · JNJHealthcarePharmaceuticals

Johnson & Johnson financials

$267.57−1.61%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

QuarterQ2 '26
Jun 28
Q1 '26
Mar 29
Q4 '25
Dec 28
Q3 '25
Sep 28
Q2 '25
Jun 29
Q1 '25
Mar 30
Q4 '24
Dec 29
Q3 '24
Sep 29
Q2 '24
Jun 30
Q1 '24
Mar 31
Q4 '23
Dec 31
Q3 '23
Oct 1
Revenue$25.31B$24.06B$24.56B$23.99B$23.74B$21.89B$22.52B$22.47B$22.45B$21.38B$21.39B$21.35B
Gross profit$17.26B$15.96B$16.60B$16.69B$16.11B$14.54B$15.39B$15.51B$15.58B$14.87B$14.60B$14.74B
Gross margin68.2%66.3%67.6%69.6%67.9%66.4%68.3%69.0%69.4%69.6%68.2%69.1%
Operating income$7.14B$6.33B$5.43B$7.03B$6.65B$6.18B$3.58B$5.04B$6.28B$5.91B$4.19B$5.53B
Net income$5.53B$5.24B$5.12B$5.15B$5.54B$11.00B$3.43B$2.69B$4.69B$3.25B$4.05B$26.03B
Net margin21.9%21.8%20.8%21.5%23.3%50.2%15.2%12.0%20.9%15.2%18.9%121.9%
Diluted EPS$2.27$2.14$2.09$2.12$2.29$4.54$1.41$1.11$1.93$1.34$1.65$10.21
EBITDA$9.13B$8.36B$7.52B$8.87B$8.65B$7.97B$5.33B$6.92B$8.24B$7.89B$4.25B$7.52B
Operating cash flow$8.62B$2.51B$7.31B$9.17B$3.88B$4.17B$6.98B$7.99B$5.63B$3.66B$7.86B$7.49B
Free cash flow$7.29B$1.47B$5.09B$8.38B$2.83B$3.38B$3.59B$6.96B$4.66B$2.85B$5.80B$6.52B
Diluted shares2,440.1M2,445.2M2,446.1M2,428.6M2,419.1M2,423.8M2,437.6M2,427.9M2,422.0M2,430.1M2,460.7M2,549.7M

Balance sheet

Period endJun 28Mar 29Dec 28Sep 28Jun 29Mar 30
Cash & equivalents$20.42B$21.69B$19.71B$18.23B$18.58B$38.47B
Short-term investments$336.0M$363.0M$393.0M$331.0M$303.0M$307.0M
Total debt$49.04B$54.99B$47.93B$45.80B$50.76B$52.25B
Total assets$201.06B$200.89B$199.21B$192.82B$193.39B$193.67B
Total liabilities$116.09B$119.71B$117.67B$113.54B$114.92B$115.56B
Shareholders' equity$84.97B$81.19B$81.54B$79.28B$78.47B$78.11B

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology